Blastic natural killer cell lymphoma/leukemia (CD56‐positive blastic tumor)
Open Access
- 5 July 2005
- Vol. 104 (5), 1022-1031
- https://doi.org/10.1002/cncr.21268
Abstract
BACKGROUND Blastic natural killer (NK) cell lymphoma/leukemia (BNKL) is an immature CD56‐positive neoplasm, which was recognized recently and characterized by systemic proliferation of tumor cells including skin, lymph node, and bone marrow. METHODS The current study analyzed 47 patients with BNKL (27 had leukemias and 20 had lymphomas). Patient data were collected for the survey of the NK‐Cell Tumor Study Group. RESULTS There were 33 males and 14 females, with a median age of 53 years (range, 3 months to 89 years). There were few clinicopathologic differences between the leukemia and lymphoma types. Cutaneous involvement was noted at diagnosis in 28 patients, who presented a tendency for older age of onset (median: 56 vs. 46 years, P = 0.11) than patients with noncutaneous BNKL. Cutaneous BNKL showed less frequent mediastinal involvement (4% vs. 53%, P = 0.0002) and less severe thrombocytopenia (P =0 .03). Phenotypic characteristics were also different, with cutaneous BNKL favoring CD4 and HLA‐DR expression, and noncutaneous BNKL favoring CD16 and CD34 expression. Both groups responded well to chemotherapy for lymphoid malignancies, but disease recurrence was frequent. The prognosis of patients with noncutaneous BNKL was significantly poorer than that of patients with cutaneous BNKL (median survival: 15 vs. 25 months, P = 0.02). Multivariate analysis confirmed that cutaneous involvement was a significant and independent prognostic factor for BNKL, as were age of onset and leukocyte count. CONCLUSIONS These findings suggested that BNKL is a heterogeneous disease and contains at least two subtypes. Although further investigations are needed to settle a marker for distinction, the presence of cutaneous involvement is a useful prognostic factor. Cancer 2005. © 2005 American Cancer Society.Keywords
This publication has 56 references indexed in Scilit:
- Childhood blastic NK cell leukemia successfully treated with L‐asparagenase and allogeneic bone marrow transplantationPediatric Blood & Cancer, 2004
- Successful treatment of relapsed blastic natural killer cell lymphoma with unrelated cord blood transplantationBone Marrow Transplantation, 2002
- Pediatric Acute Blastic Natural Killer Cell LeukemiaLeukemia & Lymphoma, 2002
- Precursor B-Cell Lymphoblastic LymphomaAmerican Journal of Clinical Pathology, 2001
- An Infant with Precursor Natural Killer (NK) Cell Leukemia Successfully Treated with an Unrelated Cord Blood TransplantationLeukemia & Lymphoma, 2000
- Blastic NK-cell lymphoma expressing terminal deoxynucleotidyl transferase with Homer-Wright type pseudorosettes formationHistopathology, 1998
- Lymphoblastic lymphoma of natural killer cell origin, presenting as pancreatic tumourHistopathology, 1998
- CD56-positive cutaneous lymphoma: a poorly recognized entity in the spectrum of primary cutaneous diseaseBritish Journal of Dermatology, 1997
- Recognition of unusual presentation of natural killer cell leukemiaAmerican Journal of Hematology, 1995
- Functional p75 interleukin‐2 receptor expression on the fresh blast cells in childhood acute lymphoblastic leukemia with natural killer cell propertiesAmerican Journal of Hematology, 1991